Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis

References

• Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int. 2012;12(3):388–96. doi:10.1111/j.1447-0594.2012.00851.x
   PubMed Web of Science ®Google Scholar
• Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med. 2011;27(3):355–63. doi:10.1016/j.cger.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Jang MK, Park C, Hong S, Li H, Rhee E, Doorenbos AZ. Skeletal muscle mass change during chemotherapy: A systematic review and meta-analysis. Anticancer Res. 2020;40(5):2409–18. doi:10.21873/anticanres.14210
   PubMed Web of Science ®Google Scholar
• Ligibel JA, Schmitz KH, Berger NA. Sarcopenia in aging, obesity, and cancer. Transl Cancer Res. 2020;9(9):5760–71. doi:10.21037/tcr-2019-eaoc-05
   PubMed Web of Science ®Google Scholar
• Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu X. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med. 2020;9(21):7964–78. doi:10.1002/cam4.3428
   PubMed Web of Science ®Google Scholar
• Dunne RF, Loh KP, Williams GR, Jatoi A, Mustian KM, Mohile SG. Cachexia and sarcopenia in older adults with cancer: A comprehensive review. Cancers (Basel). 2019;11(12):1861. doi:10.3390/cancers11121861
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou X, Ma B, Xing Y, Jiang X, Wang Z. Predictive value of preoperative sarcopenia in patients with gastric cancer: a meta-analysis and systematic review. J Gastrointest Surg. 2018;22(11):1890–902. doi:10.1007/s11605-018-3856-0
   PubMed Web of Science ®Google Scholar
• Borggreve AS, den Boer RB, van Boxel GI, de Jong PA, Veldhuis WB, Steenhagen E, van Hillegersberg R, Ruurda JP. The predictive value of low muscle mass as measured on CT scans for postoperative complications and mortality in gastric cancer patients: a systematic review and meta-analysis. JCM. 2020;9(1):199. doi:10.3390/jcm9010199
   Web of Science ®Google Scholar
• Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10–22. doi:10.1007/s10120-018-0882-2
   PubMed Web of Science ®Google Scholar
• Chandra R, Balachandar N, Wang S, Reznik S, Zeh H, Porembka M. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Ther. 2020;28(5):390–9. doi:10.1038/s41417-020-00234-z
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, van Laarhoven HWM. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019;10(1):199–206. doi:10.1002/jcsm.12371
   PubMed Web of Science ®Google Scholar
• Hayashi N, Ando Y, Gyawali B, Shimokata T, Maeda O, Fukaya M, Goto H, Nagino M, Kodera Y. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncol Rep. 2016;35(3):1727–31. doi:10.3892/or.2015.4475
   PubMed Web of Science ®Google Scholar
• Kano M, Hihara J, Tokumoto N, Kohashi T, Hara T, Shimbara K, Takahashi S. Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients. Int J Clin Oncol. 2021;26(3):523–31. doi:10.1007/s10147-020-01833-4
   PubMed Web of Science ®Google Scholar
• Kim Y-Y, Lee J, Jeong WK, Kim ST, Kim J-H, Hong JY, Kang WK, Kim K-M, Sohn I, Choi D, et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 2021;24(2):457–66. doi:10.1007/s10120-020-01124-x
   PubMed Web of Science ®Google Scholar
• Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT determined sarcopenia in patients with advanced gastric cancer. PLoS One. 2018;13(8):e0202700. doi:10.1371/journal.pone.0202700
   PubMed Web of Science ®Google Scholar
• Ma LX, Taylor K, Espin‐Garcia O, Anconina R, Suzuki C, Allen MJ, Honorio M, Bach Y, Allison F, Chen EX, et al. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. Cancer Med. 2021;10(1):199–207. doi:10.1002/cam4.3604
   PubMed Web of Science ®Google Scholar
• Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, Park J-M, Chi K-C, Hwang IG. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep. 2020;10(1):17683. doi:10.1038/s41598-020-74765-8
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses – 2008. [accessed April 2021]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp..
   Google Scholar
• Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149(12):889–97. doi:10.7326/0003-4819-149-12-200812160-00008
   PubMed Web of Science ®Google Scholar
• Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. doi:10.1186/1471-2288-6-31
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. doi:10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clin Nutr. 2021;40(10):5298–310. doi:10.1016/j.clnu.2021.08.023
   PubMed Web of Science ®Google Scholar
• Zeng Z, Yang B, Liao Z. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Future Oncol. 2021;17(12):1553–69. doi:10.2217/fon-2020-0829
   PubMed Web of Science ®Google Scholar
• Yoneda A, Kuroki T, Eguchi S. Immunotherapeutic advances in gastric cancer. Surg Today. 2021;51(11):1727–35. doi:10.1007/s00595-021-02236-2
   PubMed Web of Science ®Google Scholar
• Albano D, Messina C, Vitale J, Sconfienza LM. Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2020;30(4):2199–208. doi:10.1007/s00330-019-06573-2
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel J-P, Rolland Y, Schneider SM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. doi:10.1093/ageing/afq034
   PubMed Web of Science ®Google Scholar
• Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–7.e2. doi:10.1016/j.jamda.2019.12.012
   PubMed Web of Science ®Google Scholar